首页 > 市场调查报告书 > 医疗设备

医学影像诊断癌症个人化医学分子呈像/呈影剂核子医学

2028 年放射性药物治疗市场预测——按 COVID-19 产品类型,放射性同位素,来源,应用,适应症和最终用户划分的影响和全球分析

市场调查报告书

商品编码

1263754

2028 年放射性药物治疗市场预测——按 COVID-19 产品类型,放射性同位素,来源,应用,适应症和最终用户划分的影响和全球分析

Radiopharmaceutical Theranostics Market Forecast to 2028 - Global Analysis By Product Type, Radioisotope, Source, Application, Indication, and End User

出版日期: 2023年03月27日 | 出版商:

The Insight Partners | 英文 185 Pages | 订单完成后即时交付

价格

简介目录图表

放射性药物治疗诊断市场预计将从 2022 年的 18.1458 亿美元增长到 2028 年的 34.4197 亿美元，从 2022 年到 2028 年的复合年增长率为 11.3%。癌症发病率上升和在心血管疾病治疗中的应用不断增加是推动市场发展的主要因素。然而，有关批准放射性药物治疗学的监管挑战阻碍了放射性药物治疗学市场的增长。

放射性药物在癌症的诊断和治疗中具有重要意义。用 123I,124I 或低活性 131I-碘化物进行诊断扫描后，用高活性 131I-碘化物进行治疗。类似地，肾上腺素能肿瘤如嗜铬细胞瘤和神经母细胞瘤可以用 123 I-间碘苯甲基胍成像并用 131 I-间碘苯甲基胍治疗。骨闪烁扫描可用于选择患有晚期,疼痛性前列腺癌骨转移的患者。发射 BETA 或 ALPHA 粒子的骨闪烁扫描术是对这些患者的有效治疗方法。用于诊断和治疗神经内分泌肿瘤的生长抑素受体靶向□，分别是 68Ga-DOTATATE 和 177Lu-DOTATATE，是最近建立的治疗诊断学之一。

癌症是世界上导致死亡的主要原因之一，据说到 2020 年将有大约 1000 万人，即近六分之一的人死于癌症。最常见的癌症类型是乳腺癌,肺癌,结肠癌,直肠癌和前列腺癌。根据 2020 年国家癌症登记计划报告，印度男性癌症患者人数预计将在 2020 年进一步增加至 679,421 人，到 2025 年约为 763,575 人，而女性癌症患者人数预计将在 2020 年增加至 712,758 人，并且估计为 806,218。随着年龄的增长，我们的免疫系统会减弱，我们更有可能屈服于患癌症的风险。不良的生活习惯,长时间的工作,压力增加,吸烟,饮酒,使用避孕药具,未婚和减少母乳喂养都是导致乳腺癌发生的因素。

根据美国癌症协会 2023 年的报告，2023 年将记录到约 43,720 例甲状腺癌新病例（12,540 名男性和 31,180 名女性）。据透露，同年将有 2,120 人死于甲状腺癌（970 名男性和 1,150 名女性）。放射性药物治疗诊断学在癌症治疗中具有广阔的前景。治疗诊断学是使用适当放射性药物的治疗和诊断技术的组合。例如，放射性碘在分化型甲状腺癌的诊断和治疗中具有众所周知的治疗应用。几种放射性药物可用于乳腺癌应用。这些对包括 43/44Sc/47Sc,64Cu/67Cu,83Sr/89Sr,86Y/90Y,110In/111In,124I/131I,152Tb/161Tb,152Tb/149Tb,68Ga/177Lu 和 90Y/177Lu。 123I/131I 是用于甲状腺癌治疗前后评估的高质量单光子发射计算机断层扫描 (SPECT)/CT 的治疗诊断对的一个着名示例。

恶性神经胶质瘤是一种致命的肿瘤，治疗选择有限。 89Zr 和 177Lu 标记的 Lumi804-ALPHACD11b 是一种很有前途的治疗诊断技术，旨在监测和减少胶质瘤中的肿瘤相关髓样细胞 (TAMC) 并改善免疫治疗结果。此外，治疗诊断学已被纳入用于 PET 成像和靶向放射性药物治疗 (TRT) 的放射性药物中。用 Lu-177（177Lu-dotatate：Lutathera）或 Ga-68（68Ga-dotatate：NetSpot）放射性标记的 DOTA-octreotate（dotatate）已被 FDA（食品和药物管理局）批准用于靶向放射性药物治疗（TRT）。）和正电子发射断层扫描 (PET) 成像。因此，放射性药物治疗诊断方法在各类癌症的诊断和治疗中具有前所未有的价值，推动了整个放射性药物治疗诊断市场的增长。

产品类型洞察

放射性药物治疗诊断学市场根据产品类型分为正电子发射断层扫描 (PET) 示踪剂,BETA 发射体和 ALPHA 发射体。到 2022 年，正电子发射断层扫描 (PET) 示踪剂部分将在放射性药物治疗市场中占据最大的市场份额，预计在预测期内（2022-2028 年）的复合年增长率最高。 PET 是一种成像技术，可提供有关 PET 放射性药物生物分布的定量信息。 PET 成像需要昂贵的设备，例如用于放射性核素生产的迴旋加速器,自动化化学和纯化设备以及 PET 相机。 PET 成像用于心脏病学,神经病学和癌症诊断等领域。 PET 可以在其他成像测试揭示疾病之前及早发现疾病的发作。使用正电子发射器（例如镓 68 和氟 18）的 PET 可以获得更高的分辨率。由于其高膜渗透性和低氧化还原电位，放射性铜也被开发为一种有前途的示踪剂，以取代现有的缺氧成像技术。 Ga-PSMA-11 的成功进一步刺激了用于前列腺癌成像的 PSMA 靶向 PET 示踪剂的开发。此外，治疗诊断学 PET 示踪剂越来越多地用于放射性药物的开发和应用。作为一种非侵入性系统导航器，治疗诊断学 PET 示踪剂可能有助于选择最有效的候选药物,最佳剂量和给药途径。因此，高分辨率和活动量化等优势正在推动 PET 示踪剂领域的放射性药物治疗市场。

放射性同位素见解

基于放射性同位素，放射性药物治疗诊断学市场包括橹 (Lu) 177,镓 68,碘 131,碘 123,鎝 99,钇 90 (Y-90),铜 (Cu) 64,18F ，铜（Cu）67等。到 2022 年，橹 (Lu) 177 细分市场将在放射性药物治疗市场中占据最大的市场份额，预计在预测期内（2022-2028 年）的复合年增长率最高，达到 12.3%。 Lutetium-177（177Lu）是核医学领域的新成员。它有可能在未来几年内成为使用最广泛的治疗用放射性核素之一。用于癌症治疗的 Lu-177 PSMA 疗法已用于治疗晚期前列腺癌病例。 Lu-177 octreotate 疗法用于治疗神经内分泌肿瘤 (NETs)，包括头颈癌和胃肠道肿瘤。橹疗法（lutetium-177-DOTA-oxodotreotide）已被确定为靶向核素疗法或□受体放射性核素疗法（PRRT）。美国食品和药物管理局 (FDA) 已批准 177Lu 标记的 DOTA-TATE 用于□受体放射性核素治疗 (PRRT)。

来源：洞察力

放射性药物治疗市场根据来源分为迴旋加速器和核反应堆。在 2022 年的放射性药物治疗市场中，迴旋加速器部分将占据很大的市场份额，预计在预测期内（2022-2028 年）的复合年增长率将更高。迴旋加速器最适合生产富质子放射性同位素，例如氟 18 (18F)。市售的迴旋加速器生产的医用放射性同位素包括 Carbon-11,Nitrogen-13,Oxygen-15,Fluorine-18 (18F),Copper-64,Gallium-67,Iodine-123 和 thallium-201。根据国际原子能机构 (IAEA) 2023 年报告，迴旋加速器中最常产生的放射性同位素半衰期较短，尤其是氟 18,碳 11,氧 15 和氮 13。用于正电子发射等成像技术断层扫描（PET）。迴旋加速器占 PET 所用放射性药物产量的近 95%。由于放射性核素主要用于研究,诊断和治疗各种危及生命的疾病，如癌症,帕金森病,阿尔茨海默病和失眠，因此对迴旋加速器的需求也在增加。此外，PET 和 SPECT 等医学成像技术依赖迴旋加速器产生的放射性同位素。

应用洞察

根据应用，放射性药物治疗诊断学市场分为靶向治疗 (Rx) 和伴随诊断 (CDx)。在 2022 年的放射性药物治疗市场中，靶向治疗 (Rx) 细分市场占据主要市场份额，预计在预测期内将实现更高的复合年增长率。靶向治疗已成为治疗不良临床病症（如癌症）的有前途的策略。例如，“放射性核素”是一种放射疗法，它使用细胞靶向分子，如单克隆抗体，注入体内。此外，细胞靶向分子与癌细胞上的特定靶分子结合，杀死靶向癌细胞并最大限度地减少对正常细胞的伤害。靶向疗法用于治疗前列腺癌和其他癌症。在以下针对神经内分泌胰腺肿瘤中的生长抑素受体的案例中，这一点得到了最好的理解。

68Ga 正在开髮用于生长抑素受体成像，例如 DOTATOC,DOTATATE 和 DOTANOC。生长抑素受体靶向治疗可用于新辅助治疗，使用 177Lu-DOTATATE (27) 和 90Y-DOTATATE (28) 使不能手术的 pNETs 可切除。 90Y 是一种发射 BETA 的放射性核素，最适合胰腺的大肿瘤。此外，177Lu-DOTATOC和213Bi-DOTATOC表现出较高的生物学效应，在降低胰腺癌细胞活力方面发挥了有效作用。

适应症洞察

根据适应症，放射性药物治疗诊断学市场分为肿瘤学,神经学,心脏病学等。在 2022 年的放射性药物治疗市场中，肿瘤学部分将占据最大的市场份额，预计在预测期内（2022-2028 年）的复合年增长率最高。治疗诊断学涉及将纳米粒子注入患者体内并使用光动力疗法，为个性化医疗铺平了道路。这些方法可用于治疗食管癌,前列腺癌,乳腺癌,光化性角化病,光化性唇炎,Bowen病,基底细胞上皮瘤和黄斑变性。用于癌症治疗的放射性药物主要是用BETA发射放射性核素标记的。如i-131,Lu-177,钇90(Y-90)放射性核素经常用于此目的。衰变后，释放的 BETA 粒子失去能量并穿过组织 1-12 毫米，对细胞造成细胞毒性损伤并诱导细胞凋亡。或者，最近，已经探索了 At-211 和 Ac-225 等 ALPHA 发射放射性核素的治疗用途。治疗诊断学已被临床医生和患者成功用于治疗前列腺癌。因此，在预测期内，肿瘤学对这些疗法和靶向疗法的强烈临床需求继续推动肿瘤学细分市场。

最终用户洞察

根据最终用户，放射性药物治疗市场分为医院,诊断影像中心,学术和研究机构等。到 2022 年，医院部分将占据全球放射性药物治疗市场的最大市场份额。然而，学术和研究机构部分预计在预测期内（2022-2028 年）的复合年增长率最高。该医院采用技术先进的系统来治疗心臟动脉瘤,神经动脉瘤,肿瘤和其他类似疾病。各种疾病患病率的上升和医院数量的增加促进了医院放射性药物治疗市场的增长。

内容

第一章介绍

调查范围
Insight Partners 研究报告指南
市场细分
- 放射性药物治疗诊断学的全球市场 - 按产品类型
- 放射性药物治疗诊断学的世界市场 - 按放射性同位素分类
- 放射性药物治疗诊断学的世界市场 - 按供应商分类
- 全球放射性药物治疗市场 - 按应用分类
- 全球放射性药物治疗市场 - 按适应症分类
- 全球放射性药物治疗市场 - 最终用户
- 世界放射性药物治疗市场市场 - 按地区

第 2 章放射性药物治疗市场 - 要点

第三章研究方法论

报导
二次调查
关于初步调查

第 4 章放射性药物治疗市场 - 市场格局

害虫分析
- 北美 PEST 分析
- 欧洲 PEST 分析
- 亚太地区 PEST 分析
- 拉丁美洲 PEST 分析
- 中东和非洲 PEST 分析
专家意见

第 5 章放射性药物治疗市场 - 主要市场动态

市场驱动因素
- 癌症发病率增加
- 在心血管疾病治疗中的应用进展
市场製约因素
- 批准放射性药物治疗的监管挑战
市场机会
- 用于放射性药物个性化治疗的治疗诊断数字孪生
未来趋势
- 核医学中的放射性药物治疗诊断学
影响分析

第 6 章放射性药物治疗市场 - 全球分析

放射性药物治疗诊断学的全球市场收入和预测/分析
放射性药物治疗学全球市场,区域预测和分析
主要参与者的市场定位
- GE HealthCare Technologies Inc
- Curium

第 7 章全球放射性药物治疗市场 - 按产品类型划分的收入和到 2028 年的预测

全球放射性药物治疗市场，2021 年和 2028 年按产品类型划分的销售额份额 (%)

第 8 章放射性药物治疗诊断学的全球市场分析 - 按放射性同位素

全球放射性药物治疗市场，2021 年和 2028 年按放射性同位素划分的销售额份额 (%)

第 9 章放射性药物治疗诊断学的全球市场分析 - 按来源

全球放射性药物治疗市场，2021 年和 2028 年按来源划分的收入份额 (%)

第 10 章放射性药物治疗诊断学的全球市场分析 - 按应用

2021 年和 2028 年全球放射性药物治疗诊断学市场按应用划分的收入份额 (%)

第 11 章放射性药物治疗诊断学的全球市场分析 - 按适应症

全球放射性药物治疗市场，2021 年和 2028 年按适应症划分的销售份额 (%)

第 12 章放射性药物治疗的全球市场分析 - 按最终用户

全球放射性药物治疗市场，2021 年和 2028 年最终用户的销售份额 (%)

第 13 章放射性药物治疗市场 - 收入和到 2028 年的预测 - 区域分析

北美
- 美国
- 加拿大
- 墨西哥
欧洲
- 德国
- 英国
- 法国
- 意大利
- 西班牙
- 其他欧洲
亚太地区
- 中国
- 日本
- 印度
- 韩国
- 澳大利亚
- 其他亚太地区
中东和非洲
- 沙特阿拉伯
- 南非
- 阿联酋
- 其他中东和非洲地区
拉丁美洲
- 巴西
- 阿根廷
- 其他南美洲和中美洲

第 14 章 COVID-19 大流行对放射性药物治疗市场的影响

北美
欧洲
亚太地区
中东和非洲
拉丁美洲

第 15 章放射性药物治疗市场 - 行业格局

放射性药物治疗市场的增长战略
无机增长战略
有机增长战略

第十六章公司简介

Bayer AG
GE HealthCare Technologies Inc
Curium
Lantheus Medical Imaging, Inc.
Telix Pharmaceuticals Ltd.
Cardinal Health Inc
Advanced Accelerator Applications S.A.
Jubilant Radiopharma
Theragnostics
NuView Life Sciences

第十七章附录

关于 Insight Partners
词彙表

简介目录图表

Product Code: TIPRE00024328

The radiopharmaceutical theranostics market is expected to reach US$ 3,441.97 million by 2028 from US$ 1,814.58 million in 2022; it is estimated to grow at a CAGR of 11.3% from 2022 to 2028. The rising incidence of cancer and rising application in treatment of cardiovascular disorder are among the key forces bolstering the market. However, regulatory challenges for the approval of radiopharmaceutical theranostics hinder the radiopharmaceutical theranostics market growth.

Radiopharmaceuticals are important in the diagnosis and therapy of cancer; a diagnostic scan with 123I, 124I, or low-activity 131I-iodide is followed by therapy with high-activity 131I-iodide. Similarly, adrenergic tumors such as pheochromocytoma and neuroblastoma can be imaged with 123 I-meta-iodobenzylguanidine and treated with 131 I-metaiodobenzylguanidine. Bone scintigraphy can be used to select patients with painful bone metastases that progressed from prostate cancer. They might benefit from treatment with beta- or alpha-particle-emitting bone-seeking agents, the newest and most successful of which is 223Ra radium chloride. Somatostatin receptor targeting peptides for diagnosing and treating neuroendocrine tumors with agents such as 68Ga-DOTATATE and 177Lu-DOTATATE, respectively, are among the recently established theranostics.

Cancer is one of the leading causes of death worldwide, responsible for almost 10 million deaths in 2020, or almost one in six. The most common types of cancer are breast, lung, colon, rectum, and prostate. According to National Cancer Registry Program Report 2020, in India, male cancer cases were estimated at 679,421 in 2020 and are expected to further increase to about 763,575 in 2025, while female cancer cases were estimated at 712,758 in 2020 and 806,218 in 2025. As people age, they become immunocompromised and often succumb to cancer risks. Poor lifestyles, longer working hours, increasingly stressful lives, smoking, alcohol consumption, contraceptive use, nulliparity, and reduced breastfeeding all contribute to breast cancer incidence.

According to the American Cancer Society's 2023 report, ~43,720 new cases of thyroid cancer (12,540 in men and 31,180 in women) are recorded in 2023. The report also revealed that 2,120 deaths occurred from thyroid cancer (970 in men and 1,150 in women) in the same year. Radiopharmaceutical theranostics have promising potential in cancer therapy. Theranostics is the combination of therapeutic and diagnostic techniques that utilize a suitable radiopharmaceutical agent. For example, radioiodine has a well-known theranostic application in diagnosing and treating differentiated thyroid cancer. Several radiopharmaceutical theranostic pairs are available for breast cancer applications. These pairs include 43/44Sc/47Sc, 64Cu/67Cu, 83Sr/89Sr, 86Y/90Y, 110In/111In, 124I/131I, 152Tb/161Tb, 152Tb/149Tb, 68Ga/177Lu, and 90Y/177Lu. 123I/131I is a well-known example of theranostic pair that is used in high-quality single-photon emission computerized tomography (SPECT)/CT for pre- and post-therapeutic assessment of thyroid cancer.

Malignant gliomas are deadly tumors with the availability of only a few therapeutic options. 89Zr- and 177Lu-labeled Lumi804-αCD11b is a promising theranostic technique intended for monitoring and reducing tumor-associated myeloid cells (TAMCs) in gliomas and improving immunotherapy outcomes. Further, theranostics are incorporated in radiometals for PET imaging and targeted radiopharmaceutical therapy (TRT). DOTA-octreotate (dotatate) radiolabeled with Lu-177 (177Lu-dotatate: Lutathera) or Ga-68 (68Ga-dotatate: NetSpot) are approved by the Food and Drug Administration (FDA) for targeted radiopharmaceutical therapy (TRT) and positron emission tomography (PET) imaging. Thus, a radiopharmaceutical theranostic approach has unprecedented value in diagnosing and treating different types of cancer, which fuels the overall radiopharmaceutical theranostics market growth.

Product Type Insights

Based on product type, the radiopharmaceutical theranostics market is segmented positron emission tomography (PET) tracers, beta emitters, and alpha emitters. In 2022, the positron emission tomography (PET) tracers segment held the largest market share in radiopharmaceutical theranostics market, and it is anticipated to register the highest CAGR during the forecast period (2022-2028). PET is an imaging technique that provides quantitative information on the distribution of PET radiopharmaceuticals in the body. PET imaging requires expensive equipment, which includes a cyclotron for radionuclide production, automated chemistry devices, purification instrumentation, and PET cameras. PET imaging is used in areas such as cardiology, neurology, and cancer diagnosis. PET may detect the early onset of disease before it is evident on other imaging tests. Better resolution can be achieved via PET using positron emitters, such as gallium-68 and fluorine-18. PET tracers featuring radioactive copper have also been developed as a promising alternative for existing hypoxia imaging techniques due to their high membrane permeability and low redox potential. The success of Ga-PSMA-11 further inspired the development of PSMA-targeting PET tracers for imaging prostate cancer. Additionally, theranostics PET tracers are progressively used in radiopharmaceutical drug development and its application. Theranostic PET tracers have the potential to serve as a noninvasive whole-body navigator, which helps select the most effective drug candidates, and determine optimal dosage and administration route. Thus, benefits such as higher resolution, and quantification of activity boost the radiopharmaceutical theranostics market for the PET tracers segment.

Radioisotope Insights

Based on radioisotope, the radiopharmaceutical theranostics market is segmented Lutetium (Lu) 177, Gallium-68, Iodine-131, Iodine-123, Technetium-99, Yttrium-90 (Y-90), Copper (Cu) 64, 18F, Copper (Cu) 67, and others. In 2022, the Lutetium (Lu) 177 segment held the largest market share in radiopharmaceutical theranostics market, and it is anticipated to register the highest CAGR of 12.3% during the forecast period (2022-2028). Lutetium-177 (177Lu) is the latest addition to the field of nuclear medicine. It has potential to become one of the most extensively used therapeutic radionuclides in the coming years. Lu-177 PSMA therapy for cancer theranostic is employed to treat advanced prostate cancer cases. Lu-177 octreotate therapy is used to treat neuroendocrine tumors (NETs), including head and neck cancers and gastrointestinal tumors. Lutetium therapy (lutetium-177-DOTA-oxodotreotide) has been identified as targeted radionuclide therapy or peptide receptor radionuclide therapy (PRRT). The US Food and Drug Administration (FDA) has approved 177Lu-labeled DOTA-TATE for peptide receptor radionuclide therapy (PRRT).

Source Insights

Based on source, the radiopharmaceutical theranostics market is divided into cyclotrons and nuclear reactors. In 2022, the cyclotrons segment held a larger market share in radiopharmaceutical theranostics market and is anticipated to register a higher CAGR during the forecast period (2022-2028). Cyclotrons are best suited for producing proton-rich radioisotopes such as Fluorine-18 (18F). Commercially available cyclotron-produced medical radioisotope involves Carbon-11, Nitrogen-13, Oxygen-15, Fluorine-18 (18F), Copper-64, Gallium-67, Iodine-123, and Thallium-201. According to the International Atomic Energy Agency (IAEA) 2023 report, the most frequent radioisotope produced through cyclotrons are those with short half-lives, particularly fluorine-18, carbon-11, oxygen-15, and nitrogen-13, intended for imaging techniques such as positron emission tomography (PET). Cyclotrons account for almost 95% of the production of radiopharmaceuticals used in PET. Additionally, the demand for cyclotrons is increasing as radionuclides are majorly used in research, diagnosis, and treatment of a range of life-threatening diseases such as cancer, Parkinson's, Alzheimer's, and insomnia. Further, medical imaging techniques such as PET and SPECT depend on cyclotron-produced radioisotopes.

Application Insights

Based on application, the radiopharmaceutical theranostics market is bifurcated into targeted therapeutic (Rx) and companion diagnostic (CDx). The targeted therapeutic (Rx) segment held a larger market share in radiopharmaceutical theranostics market in 2022, and it is expected to register a higher CAGR during the forecast period. Targeted therapeutics have emerged as a promising strategy for treating harmful clinical conditions, such as cancer. For example, "radionuclide," a type of radiation therapy, uses a cell-targeting molecule such as a monoclonal antibody injected into the body. Further, the cell-targeting molecule binds to a specific target molecule on cancer cells, subsequently killing the targeted cancer cells; the mechanism ensures minimum harm to normal cells. Targeted therapeutics are used for treating prostate cancer and other types of cancers. This is well understood by the following case of targeting somatostatin receptors in neuroendocrine pancreatic tumors.

68Ga has been developed for somatostatin receptor imaging such as DOTATOC, DOTATATE, and DOTANOC. A somatostatin-receptor targeted therapy can be utilized for neoadjuvant therapy that renders inoperable pNET resectable by utilizing 177Lu-DOTATATE (27) and 90Y-DOTATATE (28). 90Y is a beta-emitting radionuclide best suited for bulky pancreatic tumors. Additionally, 177Lu-DOTATOC and 213Bi-DOTATOC have revealed relatively high biological effectiveness, and they are effectively responsible for decreasing the survival of pancreatic adenocarcinoma cells.

Indication Insights

Based on indication, the radiopharmaceutical theranostics market is segmented oncology, neurology, cardiology, and others. The oncology segment held the largest market share in radiopharmaceutical theranostics market in 2022, and it is anticipated to register the highest CAGR during the forecast period (2022-2028). Theranostics methods involve administering nanoparticles into the patient's body and using photodynamic therapy, which paves the way for personalized medicine. These methods can be applied in the treatment of esophageal cancer, prostate cancer, and breast cancer, in the treatment of actinic keratosis, actinic cheilitis, Bowen's disease, basal cell epithelioma, and macular degeneration. Therapeutic radiopharmaceuticals for cancer treatment are predominantly labeled with beta-emitting radionuclides. The radionuclides I-131, Lu-177, and Yttrium-90 (Y-90) are frequently used for this purpose. Upon decay, the emitted beta-particles travel 1-12 mm through tissue while losing energy and causing cytotoxic damage to the cell to induce apoptosis. Alternatively, and more recently, alpha-emitting radionuclides, e.g., At-211 or Ac-225, have been explored for therapeutic applications. Theranostics has been successfully used by clinicians and patients in treating prostate cancer. Thus, the strong clinical need for these therapies and targeted treatments in oncology continue to fuel the market for the oncology segment during the forecast period.

End User Insights

Based on end user, the radiopharmaceutical theranostics market is segmented hospitals, diagnostic imaging centers, academic and research institutes, and others. The hospitals segment held the largest market share in 2022 of global radiopharmaceutical theranostics market. However, academic and research institutes segment is anticipated to register the highest CAGR during the forecast period (2022-2028). Hospitals employ technologically advanced systems to treat cardiac aneurysms, neurology aneurysms, oncology tumors, and other similar conditions. The rising prevalence of various diseases and an increasing number of hospitals contribute to the growth of the radiopharmaceutical theranostics market for hospitals segment.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the smart hospital beds market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the global smart hospital beds market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

1. Introduction

1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 Global Radiopharmaceutical Theranostics Market - by Product Type
- 1.3.2 Global Radiopharmaceutical Theranostics Market - by Radioisotope
- 1.3.3 Global Radiopharmaceutical Theranostics Market - by Source
- 1.3.4 Global Radiopharmaceutical Theranostics Market - by Application
- 1.3.5 Global Radiopharmaceutical Theranostics Market - by Indication
- 1.3.6 Global Radiopharmaceutical Theranostics Market - by End User
- 1.3.7 Global Radiopharmaceutical Theranostics Market - by Geography

2. Radiopharmaceutical Theranostics Market - Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Radiopharmaceutical Theranostics Market - Market Landscape

4.1 Overview
4.2 PEST Analysis
- 4.2.1 North America PEST Analysis
- 4.2.2 Europe PEST Analysis
- 4.2.3 Asia Pacific PEST Analysis
- 4.2.4 South & Central America PEST Analysis
- 4.2.5 Middle East & Africa PEST Analysis
4.3 Expert's Opinion

5. Radiopharmaceutical Theranostics Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Rising Incidence of Cancer
- 5.1.2 Rising Application in Treatment of Cardiovascular Disorders
5.2 Market Restraints
- 5.2.1 Regulatory Challenges for Approval of Radiopharmaceutical Theranostics
5.3 Market Opportunities
- 5.3.1 Theranostic Digital Twins for Personalized Radiopharmaceutical Therapies
5.4 Future Trends
- 5.4.1 Radiopharmaceutical Theranostics in Nuclear Medicine
5.5 Impact Analysis

6. Radiopharmaceutical Theranostics Market - Global Analysis

6.1 Global Radiopharmaceutical Theranostics Market Revenue Forecast and Analysis
6.2 Global Radiopharmaceutical Theranostics Market, by Geography - Forecast and Analysis
6.3 Market Positioning of Key Players
- 6.3.1 GE HealthCare Technologies Inc
- 6.3.2 Curium

7. Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 - by Product Type

7.1 Overview
7.2 Global Radiopharmaceutical Theranostics Market Revenue Share, by Product Type 2021 & 2028 (%)
- 7.2.1 Positron Emission Tomography (PET) Tracers
  - 7.2.1.1 Overview
  - 7.2.1.2 Positron Emission Tomography (PET) Tracers: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 7.2.2 Beta Emitters
  - 7.2.2.1 Overview
  - 7.2.2.2 Beta Emitters: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 7.2.3 Alpha Emitters
  - 7.2.3.1 Overview
  - 7.2.3.2 Alpha Emitters: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

8. Global Radiopharmaceutical Theranostics Market Analysis - by Radioisotope

8.1 Overview
8.2 Global Radiopharmaceutical Theranostics Market Revenue Share, by Radioisotope 2021 & 2028 (%)
- 8.2.1 Technetium-99
  - 8.2.1.1 Overview
  - 8.2.1.2 Technetium-99: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.2 Gallium-68
  - 8.2.2.1 Overview
  - 8.2.2.2 Gallium-68: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.3 Iodine-131
  - 8.2.3.1 Overview
  - 8.2.3.2 Iodine-131: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.4 Iodine-123
  - 8.2.4.1 Overview
  - 8.2.4.2 Iodine-123: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.5 Fluorine-18 (18F)
  - 8.2.5.1 Overview
  - 8.2.5.2 Fluorine-18 (18F): Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.6 Yttrium 90 (Y-90)
  - 8.2.6.1 Overview
  - 8.2.6.2 Yttrium 90 (Y-90): Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.7 Lutetium (LU) 177
  - 8.2.7.1 Overview
  - 8.2.7.2 Lutetium (LU) 177: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.8 Copper (CU) 67
  - 8.2.8.1 Overview
  - 8.2.8.2 Copper (CU) 67: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.9 Copper (CU) 64
  - 8.2.9.1 Overview
  - 8.2.9.2 Copper (CU) 64: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.10 Others
  - 8.2.10.1 Overview
  - 8.2.10.2 Others: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

9. Global Radiopharmaceutical Theranostics Market Analysis - by Source

9.1 Overview
9.2 Global Radiopharmaceutical Theranostics Market Revenue Share, by Source 2021 & 2028 (%)
- 9.2.1 Nuclear Reactors
  - 9.2.1.1 Overview
  - 9.2.1.2 Nuclear Reactors: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 9.2.2 Cyclotrons
  - 9.2.2.1 Overview
  - 9.2.2.2 Cyclotrons: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

10. Global Radiopharmaceutical Theranostics Market Analysis - by Application

10.1 Overview
10.2 Global Radiopharmaceutical Theranostics Market Revenue Share, by Application 2021 & 2028 (%)
- 10.2.1 Targeted Therapeutic (Rx)
  - 10.2.1.1 Overview
  - 10.2.1.2 Targeted Therapeutics (Rx): Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 10.2.2 Companion Diagnostic (CDx)
  - 10.2.2.1 Overview
  - 10.2.2.2 Companion Diagnostics (CDx): Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

11. Global Radiopharmaceutical Theranostics Market Analysis - by Indication

11.1 Overview
11.2 Global Radiopharmaceutical Theranostics Market Revenue Share, by Indication 2021 & 2028 (%)
- 11.2.1 Oncology
  - 11.2.1.1 Overview
  - 11.2.1.2 Oncology: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 11.2.2 Neurology
  - 11.2.2.1 Overview
  - 11.2.2.2 Neurology: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 11.2.3 Cardiology
  - 11.2.3.1 Overview
  - 11.2.3.2 Cardiology: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 11.2.4 Others
  - 11.2.4.1 Overview
  - 11.2.4.2 Others: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

12. Global Radiopharmaceutical Theranostics Market Analysis - by End User

12.1 Overview
12.2 Global Radiopharmaceutical Theranostics Market Revenue Share, by End User 2021 & 2028 (%)
- 12.2.1 Hospitals
  - 12.2.1.1 Overview
  - 12.2.1.2 Hospitals: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 12.2.2 Diagnostic Imaging Centers
  - 12.2.2.1 Overview
  - 12.2.2.2 Diagnostic Imaging Centers: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 12.2.3 Academic & Research Institutes
  - 12.2.3.1 Overview
  - 12.2.3.2 Academic & Research Institutes: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 12.2.4 Others
  - 12.2.4.1 Overview
  - 12.2.4.2 Others: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

13. Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 - Geographic Analysis

13.1 North America: Radiopharmaceutical Theranostics Market
- 13.1.1 Overview
- 13.1.2 North America: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 13.1.3 North America: Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
- 13.1.4 North America: Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
- 13.1.5 North America: Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
- 13.1.6 North America: Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
- 13.1.7 North America: Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
- 13.1.8 North America: Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.1.8.1 United States: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.1.8.1.1 Overview
    - 13.1.8.1.2 United States: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.1.8.1.3 United States Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.1.8.1.4 United States Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.1.8.1.5 United States Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.1.8.1.6 United States Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.1.8.1.7 United States Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.1.8.1.8 United States Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.1.8.2 Canada: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.1.8.2.1 Overview
    - 13.1.8.2.2 Canada: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.1.8.2.3 Canada Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.1.8.2.4 Canada Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.1.8.2.5 Canada Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.1.8.2.6 Canada Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.1.8.2.7 Canada Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.1.8.2.8 Canada Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.1.8.3 Mexico: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.1.8.3.1 Overview
    - 13.1.8.3.2 Mexico: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.1.8.3.3 Mexico Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.1.8.3.4 Mexico Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.1.8.3.5 Mexico Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.1.8.3.6 Mexico Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.1.8.3.7 Mexico Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.1.8.3.8 Mexico Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
13.2 Europe: Radiopharmaceutical Theranostics Market
- 13.2.1 Overview
- 13.2.2 Europe: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 13.2.3 Europe: Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
- 13.2.4 Europe: Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
- 13.2.5 Europe: Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
- 13.2.6 Europe: Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
- 13.2.7 Europe: Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
- 13.2.8 Europe: Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
- 13.2.9 Europe: Radiopharmaceutical Theranostics Market, by Country, 2021 & 2028 (%)
  - 13.2.9.1 Germany: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.2.9.1.1 Overview
    - 13.2.9.1.2 Germany Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.2.9.1.3 Germany Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.2.9.1.4 Germany Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.2.9.1.5 Germany Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.2.9.1.6 Germany Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.2.9.1.7 Germany Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.2.9.1.8 Germany Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.2.9.2 United Kingdom: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.2.9.2.1 Overview
    - 13.2.9.2.2 United Kingdom Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.2.9.2.3 United Kingdom Radiopharmaceutical Theranostics Market, by Product type, 2019-2028 (US$ Million)
    - 13.2.9.2.4 United Kingdom Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.2.9.2.5 United Kingdom Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.2.9.2.6 United Kingdom Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.2.9.2.7 United Kingdom Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.2.9.2.8 United Kingdom Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.2.9.3 France: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.2.9.3.1 Overview
    - 13.2.9.3.2 France Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.2.9.3.3 France Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.2.9.3.4 France Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.2.9.3.5 France Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.2.9.3.6 France Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.2.9.3.7 France Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.2.9.3.8 France Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.2.9.4 Italy: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.2.9.4.1 Overview
    - 13.2.9.4.2 Italy Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.2.9.4.3 Italy Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.2.9.4.4 Italy Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.2.9.4.5 Italy Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.2.9.4.6 Italy Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.2.9.4.7 Italy Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.2.9.4.8 Italy Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.2.9.5 Spain: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.2.9.5.1 Overview
    - 13.2.9.5.2 Spain Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.2.9.5.3 Spain Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.2.9.5.4 Spain Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.2.9.5.5 Spain Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.2.9.5.6 Spain Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.2.9.5.7 Spain Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.2.9.5.8 Spain Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.2.9.6 Rest of Europe: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.2.9.6.1 Overview
    - 13.2.9.6.2 Rest of Europe Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.2.9.6.3 Rest of Europe Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.2.9.6.4 Rest of Europe Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.2.9.6.5 Rest of Europe Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.2.9.6.6 Rest of Europe Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.2.9.6.7 Rest of Europe Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.2.9.6.8 Rest of Europe Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
13.3 Asia Pacific: Radiopharmaceutical Theranostics Market
- 13.3.1 Overview
- 13.3.2 Asia Pacific: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 13.3.3 Asia Pacific: Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
- 13.3.4 Asia Pacific: Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
- 13.3.5 Asia Pacific: Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
- 13.3.6 Asia Pacific: Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
- 13.3.7 Asia Pacific: Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
- 13.3.8 Asia Pacific: Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
- 13.3.9 Asia Pacific: Radiopharmaceutical Theranostics Market, by Country, 2021 & 2028 (%)
  - 13.3.9.1 China: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.3.9.1.1 Overview
    - 13.3.9.1.2 China: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.3.9.1.3 China Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.3.9.1.4 China Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.3.9.1.5 China Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.3.9.1.6 China Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.3.9.1.7 China Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.3.9.1.8 China Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.3.9.2 Japan: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.3.9.2.1 Overview
    - 13.3.9.2.2 Japan: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.3.9.2.3 Japan Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.3.9.2.4 Japan Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.3.9.2.5 Japan Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.3.9.2.6 Japan Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.3.9.2.7 Japan Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.3.9.2.8 Japan Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.3.9.3 India: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.3.9.3.1 Overview
    - 13.3.9.3.2 India: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.3.9.3.3 India Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.3.9.3.4 India Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.3.9.3.5 India Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.3.9.3.6 India Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.3.9.3.7 India Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.3.9.3.8 India Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.3.9.4 South Korea: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.3.9.4.1 Overview
    - 13.3.9.4.2 South Korea: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.3.9.4.3 South Korea Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.3.9.4.4 South Korea Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.3.9.4.5 South Korea Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.3.9.4.6 South Korea Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.3.9.4.7 South Korea Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.3.9.4.8 South Korea Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.3.9.5 Australia: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.3.9.5.1 Overview
    - 13.3.9.5.2 Australia: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.3.9.5.3 Australia Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.3.9.5.4 Australia Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.3.9.5.5 Australia Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.3.9.5.6 Australia Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.3.9.5.7 Australia Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.3.9.5.8 Australia Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.3.9.6 Rest of Asia Pacific: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.3.9.6.1 Overview
    - 13.3.9.6.2 Rest of Asia Pacific: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.3.9.6.3 Rest of Asia Pacific Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.3.9.6.4 Rest of Asia Pacific Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.3.9.6.5 Rest of Asia Pacific Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.3.9.6.6 Rest of Asia Pacific Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.3.9.6.7 Rest of Asia Pacific Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.3.9.6.8 Rest of Asia Pacific Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
13.4 Middle East & Africa Radiopharmaceutical Theranostics Market
- 13.4.1 Overview
- 13.4.2 Middle East & Africa: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 13.4.3 Middle East & Africa: Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
- 13.4.4 Middle East & Africa: Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
- 13.4.5 Middle East & Africa: Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
- 13.4.6 Middle East & Africa: Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
- 13.4.7 Middle East & Africa: Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
- 13.4.8 Middle East & Africa: Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
- 13.4.9 Middle East & Africa: Radiopharmaceutical Theranostics Market, by Country, 2021 & 2028 (%)
  - 13.4.9.1 Saudi Arabia: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.4.9.1.1 Overview
    - 13.4.9.1.2 Saudi Arabia Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.4.9.1.3 Saudi Arabia Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.4.9.1.4 Saudi Arabia Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.4.9.1.5 Saudi Arabia Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.4.9.1.6 Saudi Arabia Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.4.9.1.7 Saudi Arabia Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.4.9.1.8 Saudi Arabia Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.4.9.2 South Africa: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.4.9.2.1 Overview
    - 13.4.9.2.2 South Africa Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.4.9.2.3 South Africa Radiopharmaceutical Theranostics Market, by Product type, 2019-2028 (US$ Million)
    - 13.4.9.2.4 South Africa Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.4.9.2.5 South Africa Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.4.9.2.6 South Africa Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.4.9.2.7 South Africa Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.4.9.2.8 South Africa Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.4.9.3 UAE: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.4.9.3.1 Overview
    - 13.4.9.3.2 UAE Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.4.9.3.3 UAE Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.4.9.3.4 UAE Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.4.9.3.5 UAE Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.4.9.3.6 UAE Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.4.9.3.7 UAE Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.4.9.3.8 UAE Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.4.9.4 Rest of Middle East & Africa: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.4.9.4.1 Overview
    - 13.4.9.4.2 Rest of Middle East & Africa Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.4.9.4.3 Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.4.9.4.4 Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.4.9.4.5 Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.4.9.4.6 Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.4.9.4.7 Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.4.9.4.8 Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
13.5 South & Central America Radiopharmaceutical Theranostics Market
- 13.5.1 Overview
- 13.5.2 South & Central America: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 13.5.3 South & Central America: Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
- 13.5.4 South & Central America: Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
- 13.5.5 South & Central America: Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
- 13.5.6 South & Central America: Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
- 13.5.7 South & Central America: Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
- 13.5.8 South & Central America: Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
- 13.5.9 South & Central America: Radiopharmaceutical Theranostics Market, by Country, 2021 & 2028 (%)
  - 13.5.9.1 Brazil: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.5.9.1.1 Overview
    - 13.5.9.1.2 Brazil Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.5.9.1.3 Brazil Radiopharmaceutical Theranostics Market, by Product type, 2019-2028 (US$ Million)
    - 13.5.9.1.4 Brazil Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.5.9.1.5 Brazil Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.5.9.1.6 Brazil Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.5.9.1.7 Brazil Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.5.9.1.8 Brazil Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.5.9.2 Argentina: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.5.9.2.1 Overview
    - 13.5.9.2.2 Argentina Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.5.9.2.3 Argentina Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.5.9.2.4 Argentina Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.5.9.2.5 Argentina Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.5.9.2.6 Argentina Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.5.9.2.7 Argentina Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.5.9.2.8 Argentina Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.5.9.3 Rest of South & Central America: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.5.9.3.1 Overview
    - 13.5.9.3.2 Rest of South & Central America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.5.9.3.3 Rest of South & Central America Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.5.9.3.4 Rest of South & Central America Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.5.9.3.5 Rest of South & Central America Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.5.9.3.6 Rest of South & Central America Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.5.9.3.7 Rest of South & Central America Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.5.9.3.8 Rest of South & Central America Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)

14. Impact Of COVID-19 Pandemic on Radiopharmaceutical Theranostics Market

14.1 North America: Impact Assessment of COVID-19 Pandemic
14.2 Europe: Impact Assessment of COVID-19 Pandemic
14.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic
14.4 Middle East & Africa: Impact Assessment of COVID-19 Pandemic
14.5 South & Central America: Impact Assessment of COVID-19 Pandemic

15. Radiopharmaceutical Theranostics Market - Industry Landscape

15.1 Overview
15.2 Growth Strategies in the Radiopharmaceutical Theranostics Market
15.3 Inorganic Growth Strategies
- 15.3.1 Overview
15.4 Organic Growth Strategies
- 15.4.1 Overview

16. Company Profiles

16.1 Bayer AG
- 16.1.1 Key Facts
- 16.1.2 Business Description
- 16.1.3 Products and Services
- 16.1.4 Financial Overview
- 16.1.5 SWOT Analysis
- 16.1.6 Key Developments
16.2 GE HealthCare Technologies Inc
- 16.2.1 Key Facts
- 16.2.2 Business Description
- 16.2.3 Products and Services
- 16.2.4 Financial Overview
- 16.2.5 SWOT Analysis
- 16.2.6 Key Developments
16.3 Curium
- 16.3.1 Key Facts
- 16.3.2 Business Description
- 16.3.3 Products and Services
- 16.3.4 Financial Overview
- 16.3.5 SWOT Analysis
- 16.3.6 Key Developments
16.4 Lantheus Medical Imaging, Inc.
- 16.4.1 Key Facts
- 16.4.2 Business Description
- 16.4.3 Products and Services
- 16.4.4 Financial Overview
- 16.4.5 SWOT Analysis
- 16.4.6 Key Developments
16.5 Telix Pharmaceuticals Ltd.
- 16.5.1 Key Facts
- 16.5.2 Business Description
- 16.5.3 Products and Services
- 16.5.4 Financial Overview
- 16.5.5 SWOT Analysis
- 16.5.6 Key Developments
16.6 Cardinal Health Inc
- 16.6.1 Key Facts
- 16.6.2 Business Description
- 16.6.3 Products and Services
- 16.6.4 Financial Overview
- 16.6.5 SWOT Analysis
- 16.6.6 Key Developments
16.7 Advanced Accelerator Applications S.A.
- 16.7.1 Key Facts
- 16.7.2 Business Description
- 16.7.3 Products and Services
- 16.7.4 Financial Overview
- 16.7.5 SWOT Analysis
- 16.7.6 Key Developments
16.8 Jubilant Radiopharma
- 16.8.1 Key Facts
- 16.8.2 Business Description
- 16.8.3 Products and Services
- 16.8.4 Financial Overview
- 16.8.5 SWOT Analysis
- 16.8.6 Key Developments
16.9 Theragnostics
- 16.9.1 Key Facts
- 16.9.2 Business Description
- 16.9.3 Products and Services
- 16.9.4 Financial Overview
- 16.9.5 SWOT Analysis
- 16.9.6 Key Developments
16.10 NuView Life Sciences
- 16.10.1 Key Facts
- 16.10.2 Business Description
- 16.10.3 Products and Services
- 16.10.4 Financial Overview
- 16.10.5 SWOT Analysis
- 16.10.6 Key Developments

17. Appendix

17.1 About The Insight Partners
17.2 Glossary of Terms

简介目录图表

List Of Tables

Table 1. North America Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 2. North America Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 3. North America Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 4. North America Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 5. North America Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 6. North America Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 7. United States Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 8. United States Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 9. United States Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 10. United States Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 11. United States Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 12. United States Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 13. Canada Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 14. Canada Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 15. Canada Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 16. Canada Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 17. Canada Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 18. Canada Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 19. Mexico Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 20. Mexico Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 21. Mexico Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 22. Mexico Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 23. Mexico Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 24. Mexico Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 25. Europe Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 26. Europe Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 27. Europe Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 28. Europe Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 29. Europe Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 30. Europe Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 31. Germany Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 32. Germany Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 33. Germany Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 34. Germany Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 35. Germany Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 36. Germany Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 37. United Kingdom Radiopharmaceutical Theranostics Market, by Product type - Revenue and Forecast to 2028 (US$ Million)
Table 38. United Kingdom Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 39. United Kingdom Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 40. United Kingdom Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 41. United Kingdom Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 42. United Kingdom Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 43. France Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 44. France Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 45. France Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 46. France Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 47. France Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 48. France Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 49. Italy Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 50. Italy Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 51. Italy Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 52. Italy Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 53. Italy Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 54. Italy Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 55. Spain Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 56. Spain Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 57. Spain Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 58. Spain Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 59. Spain Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 60. Spain Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 61. Rest of Europe Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 62. Rest of Europe Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 63. Rest of Europe Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 64. Rest of Europe Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 65. Rest of Europe Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 66. Rest of Europe Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 67. Asia Pacific Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 68. Asia Pacific Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 69. Asia Pacific Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 70. Asia Pacific Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 71. Asia Pacific Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 72. Asia Pacific Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 73. China Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 74. China Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 75. China Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 76. China Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 77. China Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 78. China Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 79. Japan Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 80. Japan Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 81. Japan Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 82. Japan Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 83. Japan Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 84. Japan Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 85. India Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 86. India Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 87. India Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 88. India Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 89. India Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 90. India Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 91. South Korea Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 92. South Korea Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 93. South Korea Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 94. South Korea Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 95. South Korea Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 96. South Korea Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 97. Australia Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 98. Australia Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 99. Australia Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 100. Australia Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 101. Australia Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 102. Australia Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 103. Rest of Asia Pacific Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 104. Rest of Asia Pacific Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 105. Rest of Asia Pacific Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 106. Rest of Asia Pacific Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 107. Rest of Asia Pacific Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 108. Rest of Asia Pacific Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 109. Middle East & Africa Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 110. Middle East & Africa Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 111. Middle East & Africa Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 112. Middle East & Africa Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 113. Middle East & Africa Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 114. Middle East & Africa Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 115. Saudi Arabia Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 116. Saudi Arabia Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 117. Saudi Arabia Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 118. Saudi Arabia Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 119. Saudi Arabia Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 120. Saudi Arabia Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 121. South Africa Radiopharmaceutical Theranostics Market, by Product type - Revenue and Forecast to 2028 (US$ Million)
Table 122. South Africa Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 123. South Africa Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 124. South Africa Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 125. South Africa Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 126. South Africa Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 127. UAE Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 128. UAE Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 129. UAE Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 130. UAE Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 131. UAE Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 132. UAE Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 133. Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 134. Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 135. Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 136. Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 137. Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 138. Rest of Middle East & Africa Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 139. South & Central America Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 140. South & Central America Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 141. South & Central America Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 142. South & Central America Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 143. South & Central America Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 144. South & Central America Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 145. Brazil Radiopharmaceutical Theranostics Market, by Product type - Revenue and Forecast to 2028 (US$ Million)
Table 146. Brazil Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 147. Brazil Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 148. Brazil Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 149. Brazil Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 150. Brazil Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 151. Argentina Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 152. Argentina Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 153. Argentina Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 154. Argentina Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 155. Argentina Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 156. Argentina Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 157. Rest of South & Central America Radiopharmaceutical Theranostics Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 158. Rest of South & Central America Radiopharmaceutical Theranostics Market, by Radioisotope - Revenue and Forecast to 2028 (US$ Million)
Table 159. Rest of South & Central America Radiopharmaceutical Theranostics Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 160. Rest of South & Central America Radiopharmaceutical Theranostics Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 161. Rest of South & Central America Radiopharmaceutical Theranostics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 162. Rest of South & Central America Radiopharmaceutical Theranostics Market, by End User - Revenue and Forecast to 2028 (US$ Million)
Table 163. Recent Inorganic Growth Strategies in the Radiopharmaceutical Theranostics Market
Table 164. Recent Organic Growth Strategies in the Radiopharmaceutical Theranostics Market
Table 165. Glossary of Terms

List Of Figures

Figure 1. Radiopharmaceutical Theranostics Market Segmentation
Figure 2. Radiopharmaceutical Theranostics Market, by Region
Figure 3. Global Radiopharmaceutical Theranostics Market Overview
Figure 4. Positron Emission Tomography (PET) Tracers Segment Held Largest Share of Product Type Segment in Radiopharmaceutical Theranostics Market
Figure 5. Asia Pacific Expected to Show Remarkable Growth During Forecast Period
Figure 6. Radiopharmaceutical Theranostics Market, by Geography (US$ Million)
Figure 7. Global Radiopharmaceutical Theranostics Market - Leading Country Markets (US$ Million)
Figure 8. Global Radiopharmaceutical Theranostics Market - Industry Landscape
Figure 9. North America: PEST Analysis
Figure 10. Europe: PEST Analysis
Figure 11. Asia Pacific: PEST Analysis
Figure 12. South & Central America: PEST Analysis
Figure 13. Middle East & Africa: PEST Analysis
Figure 14. Experts' Opinion
Figure 15. Radiopharmaceutical Theranostics Market: Impact Analysis of Drivers and Restraints
Figure 16. Global Radiopharmaceutical Theranostics Market - Revenue Forecast and Analysis - 2020-2028
Figure 17. Global Radiopharmaceutical Theranostics Market, by Geography - Forecast and Analysis (2021-2028)
Figure 18. Market Positioning of Key Players in Radiopharmaceutical Theranostics Market
Figure 19. Global Radiopharmaceutical Theranostics Market Revenue Share, by Product Type 2021 & 2028 (%)
Figure 20. Positron Emission Tomography (PET) Tracers: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 21. Beta Emitters: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 22. Alpha Emitters: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 23. Global Radiopharmaceutical Theranostics Market, by Radioisotope, 2021 & 2028 (%)
Figure 24. Technetium-99: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 25. Gallium-68: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 26. Iodine-131: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 27. Iodine-123: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 28. Fluorine-18 (18F): Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 29. Yttrium 90 (Y-90): Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 30. Lutetium (LU) 177: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 31. Copper (CU) 67: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 32. Copper (CU) 64: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 33. Others: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 34. Global Radiopharmaceutical Theranostics Market, by Source, 2021 & 2028 (%)
Figure 35. Nuclear Reactors: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 36. Cyclotrons: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 37. Global Radiopharmaceutical Theranostics Market, by Application, 2021 & 2028 (%)
Figure 38. Targeted Therapeutics (Rx): Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 39. Companion Diagnostics (CDx): Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 40. Global Radiopharmaceutical Theranostics Market, by Indication, 2021 & 2028 (%)
Figure 41. Oncology: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 42. Neurology: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 43. Cardiology: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 44. Others: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 45. Global Radiopharmaceutical Theranostics Market, by End User, 2021 & 2028 (%)
Figure 46. Hospitals: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 47. Diagnostic Imaging Centers: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 48. Academic & Research Institutes: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 49. Others: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 50. North America: Radiopharmaceutical Theranostics Market, by Key Country - Revenue (2021) (US$ Million)
Figure 51. North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 52. North America: Radiopharmaceutical Theranostics Market, by Country, 2021 & 2028 (%)
Figure 53. United States: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 54. Canada: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 55. Mexico: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 56. Europe: Radiopharmaceutical Theranostics Market, by Key Country - Revenue (2021) (US$ Million)
Figure 57. Europe Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 58. Europe: Radiopharmaceutical Theranostics Market, by Country, 2021 & 2028 (%)
Figure 59. Germany Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 60. United Kingdom Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 61. France Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 62. Italy Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 63. Spain Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 64. Rest of Europe Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 65. Asia Pacific: Radiopharmaceutical Theranostics Market, by Key Country - Revenue (2021) (US$ Million)
Figure 66. Asia Pacific Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 67. China: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 68. Japan: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 69. India: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 70. South Korea: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 71. Australia: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 72. Rest of Asia Pacific: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 73. Middle East & Africa: Radiopharmaceutical Theranostics Market, by Key Country - Revenue (2021) (US$ Million)
Figure 74. Middle East & Africa Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 75. Saudi Arabia Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 76. South Africa Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 77. UAE Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 78. Rest of Middle East & Africa Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 79. South & Central America: Radiopharmaceutical Theranostics Market, by Key Country - Revenue (2021) (US$ Million)
Figure 80. South & Central America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 81. South & Central America: Radiopharmaceutical Theranostics Market, by Country, 2021 & 2028 (%)
Figure 82. Brazil Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 83. Argentina Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 84. Rest of South & Central America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 85. Impact of COVID-19 Pandemic on North American Country Markets
Figure 86. Impact of COVID-19 Pandemic in European Country Markets
Figure 87. Impact of COVID-19 Pandemic in Asia Pacific Country Markets
Figure 88. Impact of COVID-19 Pandemic in Middle East & Africa Country Markets
Figure 89. Impact of COVID-19 Pandemic on South & Central American Country Markets
Figure 90. Growth Strategies in the Radiopharmaceutical Theranostics Market